Precise Bio

Developer of integrated 3D printing and tissue-engineering platform. The platform allows the production of repeatable bio-fabricated organs from the patient's own cells for cardiology, orthopedics, dermatology, and more. The company's lead product is 3D cardiac tissue “patch” for post-myocardial infarction (MI) implant to retrieve cardiac muscle viability and functionality. Founded in 2015, headquartered in Winston-salem, United States. The company has raised $19. The company operates in the 3D Printing sector with additional focus on Life Sciences Platforms and Tools and Cardiac and Vascular Disorders. Its business model centers on 3D Bio Printers. Founded in 2015, headquartered in Winston-salem, United States. The company has raised $19.0M at the Series B stage. Backed by investors including Aurum Ventures, ZEISS, K20 Fund, 4-Good Ventures.

3D Printing > Hardware > 3D Printers > Industrial Grade > Industry Based > 3D Bio Printers,

Cardiac and Vascular Disorders > Medical Devices > Therapeutic Devices > Heart Attack,

Life Sciences Platforms and Tools > Instruments > 3D Bioprinting